When: |
11 Aug 2025 through 13 Aug 2025 | |
CFP Deadline: |
30 |
|
Where: |
Philadelphia, Pennsylvania United States | |
Website URL: |
https://cii.dryfta.com/eid/357/pid/77 | |
Sponsoring organization: |
CHI | |
Categories: |
Medicine & Health - Pharmaceutical / Medicinal |
Keywords:
Event description:
Commercializing breakthrough immune-oncology therapeutics is becoming increasingly challenging due to funding limitations, high cost and attrition rates in the clinic, regulatory uncertainties, persistent therapeutic safety and efficacy concerns, and a general lack of understanding of basic biology guiding research in this space. As we develop the 2025 conference program, we are struck by the fact that, despite these challenges, there remains a strong desire to continue to find effective therapeutics for solid tumors.
The 13th Annual Immuno-Oncology Summit showcases successes in preclinical and clinical studies grounded in a deep understanding of biology. Coverage spans solid tumor innovations, including bi/multispecific antibodies, antibody-drug conjugates (ADCs), allogenic and in vivo CAR-Ts, TILs, TCRs, Tregs, multiple cell therapies working together, the tumor microenvironment, innate immunity, gamma delta T cells, NK cells, organoid modeling, data science, and machine learni...
Read more
Posting date:
26 April 2025 | 499 views
Placement:
Not-featured (How do I make my event featured?)